OSEBX1,423.56+0.84%
EQNR284.60+4.20%
DNB198.35-1.15%
MOWI172.80+0.45%
Brent$71.24-0.32%
EUR/USD1.0824-0.14%
DXY104.18+0.08%
INDICATIVE · SAMPLE DATA
600807$3.1356

Jinan High-tech Development Co Ltd

Medical Equipment, Supplies & DistributionVerified

Jinan High-tech Development Co Ltd exhibits a highly leveraged capital structure, with a debt-to-equity ratio of 13.62. Despite a current ratio of 1.36, indicating moderate short-term liquidity, the company's free cash flow is negative at -879.6 million CNY, and its operating cash flow is only 14.1 million CNY. The company's price-to-book ratio of 35.17 suggests a significant premium to its book value, but this is not supported by positive earnings or asset returns. The company's profitability is severely underperforming relative to industry norms, with a return on equity of -10.24% and a return on assets of -0.31%. These metrics indicate a loss-making operation with no clear path to profitability. The operating income is negative at -175.9 million CNY, and the net income is -805.8 million CNY, reflecting a significant decline in operational performance. The company's revenue is concentrated in a single business segment, as disclosed in its financials, with no material geographic diversification reported. This lack of diversification increases exposure to sector-specific risks and limits growth potential. The company's revenue of 372.2 million CNY is modest, and there is no indication of significant revenue growth in the near term. The company's growth trajectory is negative, with no disclosed revenue growth in the current fiscal year and no clear outlook for improvement in the next fiscal year. The capital expenditure of -8.16 million CNY suggests minimal investment in future growth, and the company's free cash flow is insufficient to support meaningful reinvestment or debt reduction. The company faces significant financial risk, with a liquidity risk score of medium and a negative net cash position after subtracting total debt. The risk of dilution is currently low, but the company's negative equity position and high leverage increase the potential for future dilution through new equity issuance or debt restructuring. The company's valuation is not supported by fundamentals, and the high price-to-book ratio is not justified by asset quality or earnings potential. There are no recent filings or transcripts available to provide additional context on the company's operations or strategic direction. The absence of recent disclosures limits the ability to assess management's response to financial challenges or plans for recovery.

30-day price · 600807-0.25 (-7.8%)
Low$2.79High$3.32Close$2.97As of17 May, 00:00 UTC
Profile
CompanyJinan High-tech Development Co Ltd
Ticker600807.SS
SectorHealthcare
BusinessHealthcare Services & Equipment
Industry groupHealthcare Services & Equipment
IndustryMedical Equipment, Supplies & Distribution
AI analysis

Business. Jinan High-tech Development Co Ltd operates in the healthcare services and equipment industry, providing medical equipment, supplies, and distribution services.

Classification. The company is classified under the Healthcare Services & Equipment business sector with a confidence level of 0.92, and the Real Estate Management & Development industry.

Jinan High-tech Development Co Ltd exhibits a highly leveraged capital structure, with a debt-to-equity ratio of 13.62. Despite a current ratio of 1.36, indicating moderate short-term liquidity, the company's free cash flow is negative at -879.6 million CNY, and its operating cash flow is only 14.1 million CNY. The company's price-to-book ratio of 35.17 suggests a significant premium to its book value, but this is not supported by positive earnings or asset returns. The company's profitability is severely underperforming relative to industry norms, with a return on equity of -10.24% and a return on assets of -0.31%. These metrics indicate a loss-making operation with no clear path to profitability. The operating income is negative at -175.9 million CNY, and the net income is -805.8 million CNY, reflecting a significant decline in operational performance. The company's revenue is concentrated in a single business segment, as disclosed in its financials, with no material geographic diversification reported. This lack of diversification increases exposure to sector-specific risks and limits growth potential. The company's revenue of 372.2 million CNY is modest, and there is no indication of significant revenue growth in the near term. The company's growth trajectory is negative, with no disclosed revenue growth in the current fiscal year and no clear outlook for improvement in the next fiscal year. The capital expenditure of -8.16 million CNY suggests minimal investment in future growth, and the company's free cash flow is insufficient to support meaningful reinvestment or debt reduction. The company faces significant financial risk, with a liquidity risk score of medium and a negative net cash position after subtracting total debt. The risk of dilution is currently low, but the company's negative equity position and high leverage increase the potential for future dilution through new equity issuance or debt restructuring. The company's valuation is not supported by fundamentals, and the high price-to-book ratio is not justified by asset quality or earnings potential. There are no recent filings or transcripts available to provide additional context on the company's operations or strategic direction. The absence of recent disclosures limits the ability to assess management's response to financial challenges or plans for recovery.
Key takeaways
  • The company is highly leveraged with a debt-to-equity ratio of 13.62, indicating significant financial risk.
  • The company is unprofitable, with a return on equity of -10.24% and a return on assets of -0.31%.
  • The company's valuation is not supported by fundamentals, with a price-to-book ratio of 35.17 and a negative net income.
  • The company has no clear growth trajectory, with negative free cash flow and minimal capital expenditure.
  • The company's liquidity is moderate, but its negative net cash position increases financial vulnerability.
  • The company's lack of geographic and segment diversification increases exposure to sector-specific risks.
  • --
  • ## RATIONALES
Financial snapshot
PeriodHA-latest
CurrencyCNY
Revenue$372.2M
Gross profit$49.0M
Operating income-$175.9M
Net income-$805.8M
R&D
SG&A
D&A
SBC
Operating cash flow$14.1M
CapEx-$8.2M
Free cash flow-$879.6M
Total assets$2.59B
Total liabilities$2.52B
Total equity$78.7M
Cash & equivalents
Long-term debt$1.07B
Annual history (last 5)
PeriodRevenueOp IncomeNet IncomeFCF
FY0
FY-1
FY-2
FY-3
FY-4
PeriodGross %Op %Net %FCF %
FY0
FY-1
FY-2
FY-3
FY-4
PeriodAssetsEquityCashDebt
FY0
FY-1
FY-2
FY-3
FY-4
PeriodOCFCapExFCFSBC
FY0
FY-1
FY-2
FY-3
FY-4
Quarterly history (last 4)
PeriodRevenueOp IncomeNet IncomeFCF
FQ0
FQ-1
FQ-2
FQ-3
FQ-4
FQ-5
FQ-6
FQ-7
PeriodGross %Op %Net %FCF %
FQ0
FQ-1
FQ-2
FQ-3
FQ-4
FQ-5
FQ-6
FQ-7
PeriodAssetsEquityCashDebt
FQ0
FQ-1
FQ-2
FQ-3
FQ-4
FQ-5
FQ-6
FQ-7
PeriodOCFCapExFCFSBC
FQ0
FQ-1
FQ-2
FQ-3
FQ-4
FQ-5
FQ-6
FQ-7
Valuation
Market price$3.13
Market cap$2.77B
Enterprise value$3.84B
P/E
Reported non-GAAP P/E
EV/Revenue10.3
EV/Op income
EV/OCF272.9
P/B35.2
P/Tangible book35.2
Tangible book$78.7M
Net cash-$1.07B
Current ratio1.4
Debt/Equity13.6
ROA-31.1%
ROE-10.2%
Cash conversion-2.0%
CapEx/Revenue-2.2%
SBC/Revenue
Asset intensity
Dilution ratio0.0%
Risk assessment
Dilution riskLow
Liquidity riskMedium
  • Net cash is negative after subtracting total debt.
Industry benchmarks
Activity: Healthcare Services & Equipment · cohort 5 companies
Metric600807Activity
Op margin-47.3%13.3% medp25 5.9% · p75 13.5%bottom quartile
Net margin-216.5%8.6% medp25 2.7% · p75 12.7%bottom quartile
Gross margin13.2%64.0% medp25 60.1% · p75 65.6%bottom quartile
R&D / revenue6.9% medp25 6.7% · p75 7.1%
CapEx / revenue-2.2%3.0% medp25 2.7% · p75 4.5%bottom quartile
Debt / equity1362.0%69.3% medp25 63.4% · p75 74.5%top quartile
Source data
Underlying data the analysis-pipeline pulls and audits. Fetch timestamps + content hashes show when each source was last refreshed.
Company fundamentalsperiod FQ-7 · history via verified-market-data
no public URL
2026-05-07 17:54 UTC#2bca7cb8
Market quoteclose CNY 3.13 · shares 0.88B diluted
no public URL
2026-05-04 10:38 UTC#5c5d43c5
Source: analysis-pipeline (hybrid)Generated: 2026-05-04 10:40 UTCJob: 8ef113d9